Latest Cetuximab Stories
Oncologists can use colorectal cancer patients' own immune system to boost the effects of chemotherapy and increase progression-free survival.
SEATTLE, WA, April 4 /PRNewswire-FirstCall/ - Oncothyreon Inc.
Bowel cancer patients whose tumors contain defects in specific DNA repair systems are much less likely to experience tumor recurrence post surgery, results from a major clinical study have demonstrated.
Researchers at the University of Michigan Comprehensive Cancer Center have identified a potential target to treat an aggressive type of prostate cancer.
REDWOOD CITY, Calif., March 1, 2011 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, today announced the publication of preclinical data demonstrating that its lead candidate, OMP-21M18, inhibits tumor growth and reduces cancer stem cell frequency when administered alone or in combination with chemotherapy in human colorectal cancer tumors with or without KRAS mutations.
SEATTLE, March 1 /PRNewswire-FirstCall/ - Oncothyreon Inc.
MISSISSAUGA, ON, Jan. 20 /PRNewswire/ - YM BioSciences Inc.
Enrollment for a Phase I study is open for patients with a form of colorectal cancer, where the patients will be treated with a cancer biologic called REOLYSIN Calgary, Alberta (Vocus/PRWEB) January 18, 2011 Colorectal cancer is the third leading cause of cancer death among both men and women in the US.
SEATTLE, WA, Dec. 20 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux(R)).
SAN FRANCISCO and ILLKIRCH, France, Dec.
- Forsooth! indeed! originally a parenthetical phrase used in repeating the words of another with more or less contempt or disdain.